Barbara McGovern

3.6k total citations
63 papers, 1.8k citations indexed

About

Barbara McGovern is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Barbara McGovern has authored 63 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Epidemiology, 34 papers in Hepatology and 30 papers in Infectious Diseases. Recurrent topics in Barbara McGovern's work include Hepatitis C virus research (34 papers), Liver Disease Diagnosis and Treatment (23 papers) and Hepatitis B Virus Studies (23 papers). Barbara McGovern is often cited by papers focused on Hepatitis C virus research (34 papers), Liver Disease Diagnosis and Treatment (23 papers) and Hepatitis B Virus Studies (23 papers). Barbara McGovern collaborates with scholars based in United States, Canada and Australia. Barbara McGovern's co-authors include Arthur Y. Kim, Laura L. Reyor, Georg M. Lauer, Rajesh T. Gandhi, Paul E. Sax, Massimo Puoti, Alysse G. Wurcel, Vincent Soriano, Pilar García‐Gascó and Yves Benhamou and has published in prestigious journals such as JAMA, The Journal of Experimental Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Barbara McGovern

61 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara McGovern United States	22	1.2k	1.1k	648	239	172	63	1.8k
Susanna Naggie United States	33	2.1k 1.7×	1.8k 1.6×	1.0k 1.6×	308 1.3×	180 1.0×	129	3.0k
Massimo Resti Italy	32	2.3k 1.9×	1.6k 1.4×	312 0.5×	202 0.8×	64 0.4×	150	3.4k
Ray Fox United Kingdom	22	982 0.8×	793 0.7×	419 0.6×	82 0.3×	90 0.5×	41	1.4k
Carla S. Coffin Canada	33	2.4k 2.0×	2.1k 1.9×	642 1.0×	250 1.0×	76 0.4×	139	3.4k
Nancy P. Lam United States	10	1.4k 1.2×	1.6k 1.4×	332 0.5×	133 0.6×	198 1.2×	14	2.2k
Chris Taylor United Kingdom	17	559 0.5×	232 0.2×	549 0.8×	51 0.2×	149 0.9×	49	1.2k
Paola Scognamiglio Italy	20	756 0.6×	718 0.6×	476 0.7×	95 0.4×	140 0.8×	58	1.9k
Jihad Slim United States	18	594 0.5×	428 0.4×	847 1.3×	87 0.4×	397 2.3×	131	1.5k
Subrat Kumar Panda India	40	2.1k 1.8×	3.7k 3.3×	1.7k 2.6×	296 1.2×	20 0.1×	114	4.5k
A. J. Keller Australia	23	879 0.7×	751 0.7×	353 0.5×	83 0.3×	49 0.3×	63	1.9k

Countries citing papers authored by Barbara McGovern

Since Specialization

Citations

This map shows the geographic impact of Barbara McGovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara McGovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara McGovern more than expected).

Fields of papers citing papers by Barbara McGovern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara McGovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara McGovern. The network helps show where Barbara McGovern may publish in the future.

Co-authorship network of co-authors of Barbara McGovern

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara McGovern. A scholar is included among the top collaborators of Barbara McGovern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara McGovern. Barbara McGovern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bryant, Jessica A., Timothy J. Straub, Darrell S. Pardi, et al.. (2025). Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection. The Journal of Infectious Diseases. 232(5). e733–e740.

Huang, Edward S., Bret A. Lashner, Matthew Sims, et al.. (2023). 694 DURABILITY OF THE CLINICAL RESPONSE TO SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN A PHASE 3 OPEN-LABEL TRIAL (ECOSPOR IV) IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION. Gastroenterology. 164(6). S–140. 3 indexed citations

Sims, Matthew, Michael Silverman, Thomas Louie, et al.. (2023). Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection. SHILAP Revista de lepidopterología. 3(S2). s5–s5. 1 indexed citations

Garey, Kevin W., Anne J Gonzales-Luna, Brittany Lapin, et al.. (2023). Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109. JAMA Network Open. 6(1). e2253570–e2253570. 20 indexed citations

Gonzales-Luna, Anne J, et al.. (2023). 653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI). Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Louie, Thomas, Matthew Sims, Richard Nathan, et al.. (2021). 639. Time to Recurrence of Clostridioides difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic. Open Forum Infectious Diseases. 8(Supplement_1). S422–S422. 3 indexed citations

Khanna, Sahil, Darrell S. Pardi, Colleen Kelly, et al.. (2016). A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection. The Journal of Infectious Diseases. 214(2). 173–181. 230 indexed citations

Doyle, Joseph, Katja Deterding, Jason Grebely, et al.. (2015). Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. Journal of Viral Hepatitis. 22(12). 1020–1032. 8 indexed citations

Hajarizadeh, Behzad, Bart Grady, Kimberly Page, et al.. (2015). Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE. 10(4). e0122232–e0122232. 63 indexed citations

10.

Nelson, David R., K. Rajender Reddy, Adrian M. Di Bisceglie, et al.. (2014). ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients with History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials. Hepatology. 60. 5 indexed citations

11.

Hajarizadeh, Behzad, Bart Grady, Kimberly Page, et al.. (2014). Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology. 61(3). 430–434. 7 indexed citations

12.

Wiesch, Julian Schulze zur, Donatella Ciuffreda, Lia Laura Lewis‐Ximenez, et al.. (2012). Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. The Journal of Experimental Medicine. 209(1). 61–75. 180 indexed citations

13.

Grebely, Jason, Meghan D. Morris, Thomas Rice, et al.. (2012). Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. International Journal of Epidemiology. 42(6). 1649–1659. 44 indexed citations

14.

McGovern, Barbara, Ellen H. Nagami, Christopher Birch, et al.. (2009). Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection. The Journal of Infectious Diseases. 200(6). 877–881. 17 indexed citations

15.

McGovern, Barbara, et al.. (2009). Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria. Clinical Infectious Diseases. 49(7). 1051–1060. 79 indexed citations

16.

McGovern, Barbara, Christopher Birch, Ioana Bica, et al.. (2007). Managing Symptomatic Drug-Induced Liver Injury in HIV--Hepatitis C Virus--Coinfected Patients: A Role for Interferon. Clinical Infectious Diseases. 45(10). 1386–1392. 5 indexed citations

17.

McGovern, Barbara, Alysse G. Wurcel, Arthur Y Kim, et al.. (2006). Acute Hepatitis C Virus Infection in Incarcerated Injection Drug Users. Clinical Infectious Diseases. 42(12). 1663–1670. 33 indexed citations

18.

Gandhi, Rajesh T., Alysse G. Wurcel, Hang Lee, et al.. (2005). Response to Hepatitis B Vaccine in HIV‐1–Positive Subjects Who Test Positive for Isolated Antibody to Hepatitis B Core Antigen: Implications for Hepatitis B Vaccine Strategies. The Journal of Infectious Diseases. 191(9). 1435–1441. 86 indexed citations

19.

Gandhi, Rajesh T., Alysse G. Wurcel, Hwankyu Lee, et al.. (2003). Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1--Infected Individuals. Clinical Infectious Diseases. 36(12). 1602–1605. 75 indexed citations

20.

McGovern, Barbara. (2002). Evaluation and Treatment of the HIV/HCV Coinfected Patient: A Case History and Discussion. AIDS Patient Care and STDs. 16(7). 319–326. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact